Outcomes of Diabetes Management with Continuous Glucose Monitoring Technology

Abstract

Diabetes mellitus is a chronic metabolic disorder that imposes a global economic burden. Type 1 diabetes mellitus (T1DM) results from autoimmune destruction of pancreatic β-cells, while type 2 diabetes mellitus (T2DM) is characterized primarily by peripheral insulin resistance with progressive β-cell dysfunction. Despite advances in pharmacologic and self-monitoring therapies, many patients fail to achieve recommended glycemic targets. Continuous glucose monitoring (CGM) has emerged as a transformative technology with the potential to address persistent gaps in diabetes management. This review critically synthesizes the current literature on CGMassociated clinical outcomes, cost implications, and technological limitations across major commercial platforms—Dexcom, Medtronic, and FreeStyle Libre—and examines future directions in CGM innovation. A comprehensive review of randomized controlled trials, prospective cohort studies, real-world registries, and meta-analyses was performed to evaluate CGM use in T1DM and T2DM populations across pediatric, adult, and older adult cohorts. Outcomes assessed included HbA1c, time in range (TIR), hypoglycemic events, healthcare utilization, cost, patient-reported outcomes, and adverse effects. CGM use was consistently associated with improvements in glycemic control, with HbA1c reductions ranging from approximately 0.4% to 1.5% across studies, and the greatest benefits observed in patients with higher baseline HbA1c. Hypoglycemic events were substantially reduced, including a 72% reduction reported in the HypoDE trial and reductions of up to 79% in the DIAMOND trial. CGM use was also associated with increased TIR, decreased glycemic variability, and reduced rates of diabetic ketoacidosis hospitalizations and emergency department visits, yielding meaningful cost offsets despite higher upfront device costs. Patient-reported outcomes— including treatment satisfaction, self-efficacy, and quality of life—improved consistently across studies. Among the major platforms, Dexcom systems demonstrated robust evidence in both T1DM and T2DM populations; Medtronic's MiniMed 780G achieved mean TIR values approaching 78.8% with optimal settings through automated insulin delivery; and FreeStyle Libre demonstrated particular value in T2DM populations on basal insulin or noninsulin therapy. Limitations included dermatologic complications, sensor lag during rapid glycemic change, alarm fatigue, accuracy variability across the hypoglycemic range, and procedural and mechanical issues. CGM technology has fundamentally reshaped contemporary diabetes care, with consistent and reproducible benefits across glycemic, economic, and patient-centered domains in both T1DM and T2DM populations. While important device-related and patient-centered limitations persist, the cumulative evidence support broader integration of CGM into routine diabetes management. Continued innovation in sensor accuracy, automated insulin delivery, and data analytics—combined with improved access and equitable reimbursement—will be essential to fully realize the potential of CGM for the growing global diabetes population.